Breaking News: WEEDMD AND REVIVE THERAPEUTICS SIGN MEDICAL CANNABIS R&D SUPPLY AND COLLABORATION AGREEMENTS

WeedMD Inc. (OTC: WDDMF) (TSX-V: WMD), a federally-licensed producer and distributor of medical cannabis, and Revive Therapeutics Ltd. (TSX-V:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid-based therapies, are pleased to announce they have entered into medical cannabis research and development supply and collaboration agreements (the “Agreements”).

Under the Agreements, WeedMD will supply Revive with cannabidiol (“CBD”) for the research program evaluating CBD in the treatment of liver disease, specifically non-alcoholic steatohepatitis (“NASH”) and autoimmune hepatitis (“AIH”). Working alongside Revive, WeedMD will support the research, development and potential commercialization of CBD in the treatment of liver disease.  Additionally, Revive and WeedMD will identify opportunities for developing and commercializing medical cannabis products and therapies for potential collaboration in other treatments.

“The relationship with WeedMD represents a significant milestone for Revive as we have secured a strategic supply of medical-grade CBD for our research, development and commercialization efforts for liver diseases,” said Fabio Chianelli, President of Revive. “With WeedMD’s commitment to the research, development and commercialization of medical grade cannabis, they are the ideal strategic partner for Revive to accelerate the execution of our business plan in commercializing novel cannabinoid-based therapies and to validate our commercial development efforts in the medical cannabis market.”

“WeedMD continues to push ahead with its research and development initiatives, both independently and with research institutions to accelerate cannabinoid applications and delivery system innovations, in addition to collecting valuable data about strains and their effects,” said Dr. Luc Duchesne, Chief Scientific Officer of WeedMD. “Both WeedMD and Revive are making advances   as participants in the pharmaceutical cannabis market which begins with the validation of new products and innovations through clinical-evidence and the establishment of intellectual property.”

Having recently secured the intellectual property for its own delivery systems, Revive has assembled a diversified pipeline of pharmaceutical, prescription, and over the counter (OTC) products and together with WeedMD, they will evaluate the efficacy of CBD in the treatment of NASH and AIH, in addition to other potential indications in the future.

 

Sponsored Content Release. Click for Full Disclosure

 

Leave a Comment